CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
11 research outputs found
Consolidative high dose chemotherapy and autologous stem cell transplant for patients with primary central nervous system lymphoma using thiotepa, busulfan, and cyclophosphamide conditioning regimen.
Author
Davis Kipkemboi Kimaiyo
Gary J. Schiller
+5 more
Herbert Aaron Eradat
John P Chute
John Timmerman
Patricia Ann Young
Sven De Vos
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features.
Author
Adeboye H. Adewoye
Andrew David Zelenetz
+15 more
Ann Janssens
Charles Michael Farber
Christopher Pocock
Ehab L. Atallah
Herbert Aaron Eradat
Jacqueline Claudia Barrientos
Javier De La Serna
Javier Loscertales
Jennifer R. Brown
Lyndah Dreiling
Maria Aiello
Mazyar Shadman
Stephan Stilgenbauer
Steven Coutre
Yeonhee Kim
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efFicacy and safely or idelalisib (GS-1101) in combination with bendamustine and Minimal) for previously treated chronic lymphocytic leukemia (CLL).
Author
Barrlentos Jacqueline Claudia
Brown Jennifer R.
+18 more
Colffier Bertrand
Delgado Julio
Eradat Herbert Aaron
Evans Shelley
Farber Charles Michael
Ghia Paolo
Hallek Michael J.
Hillmen Peter
Jacob Abraham
Jahn Thomas Michael
Loscertales Javier
MacDonald Donald
Omyla-Staszewska Joanna
Pristupa Alexander S.
Robak Tadeusz
Schuh Anna
Sharman Jeff Porter
Zelenetz Andrew David
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2014
Field of study
No full text
Kölner UniversitätsPublikationsServer
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
Author
Barrientos Jacqueline Claudia
Cheson Bruce D.
+18 more
Coiffier Bertrand
Coutre Steven E.
Eradat Herbert Aaron
Ervin Thomas J.
Flinn Ian
Furman Richard R.
Ghia Paolo
Hallek Michael J.
Hillmen Peter
Jahn Thomas Michael
Kim Yeonhee
Kipps Thomas J.
Lamanna Nicole
O'Brien Susan Mary
Pagel John M.
Pettitt Andrew
Sharman Jeff Porter
Zelenetz Andrew David
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2014
Field of study
No full text
Kölner UniversitätsPublikationsServer
Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Author
Ahmad Halwani
Andrei R. Shustov
+16 more
Brian Poligone
Ellen J. Kim
Frederick Lansigan
Herbert Aaron Eradat
John P. Greer
Kenneth Robert Carson
Lauren C Hughey
Lisa M Grandinetti
Lubomir Sokol
Madeleine Duvic
Martine Bagot
Neil J Korman
Pier Luigi Zinzani
Pierluigi Porcu
Timothy Kuzel
Youn H. Kim
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.
Author
Ahmad Sami Halwani
Anthony R. Mato
+16 more
Brenda Chyla
Bruce D. Cheson
Herbert Aaron Eradat
Jalaja Potluri
Jeffrey Alan Jones
Leonard T. Heffner
Maria E. Verdugo
Matthew Steven Davids
Michael Y. Choi
Ming Zhu
Nicole Lamanna
Paul M. Barr
Richard R. Furman
Rod Humerickhouse
Steven Coutre
William G. Wierda
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
Author
Barrientos Jacqueline Claudia
Cheson Bruce D.
+18 more
Coiffier Bertrand
Coutre Steven E.
Eradat Herbert Aaron
Ervin Thomas J.
Flinn Ian
Furman Richard R.
Ghia Paolo
Hallek Michael J.
Hillmen Peter
Jahn Thomas Michael
Kim Yeonhee
Kipps Thomas J.
Lamanna Nicole
O'Brien Susan Mary
Pagel John M.
Pettitt Andrew
Sharman Jeff Porter
Zelenetz Andrew David
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2014
Field of study
No full text
Kölner UniversitätsPublikationsServer
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.
Author
Barrientos Jacqueline Claudia
Cheson Bruce D.
+18 more
Coiffier Bertrand
Coutre Steven E.
Eradat Herbert Aaron
Flinn Ian
Furman Richard R.
Ghia Paolo
Hallek Michael J.
Hillmen Peter
Jahn Thomas Michael
Kipps Thomas J.
Lamanna Nicole
O'Brien Susan Mary
Pagel John M.
Pettitt Andrew
Sharman Jeff Porter
Wagner Lynne I.
Ye Wei
Zelenetz Andrew David
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2014
Field of study
No full text
Kölner UniversitätsPublikationsServer
Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.
Author
Ahmad Sami Halwani
Anita G Seto
+18 more
Auris Huen
Basem M. William
Bradley Haverkos
Christiane Querfeld
Diana Escolar
Francine M. Foss
Gilad Shalag Gordon
Herbert Aaron Eradat
Jennifer DeSimone
Joan Guitart
Jud Williams
Lauren C. Pinter-Brown
Linda A Pestano
Paul Rubin
Pierluigi Porcu
Theresa Pacheco
William S. Marshall
Youn H. Kim
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
Author
Andrew David Zelenetz
Andrew Pettitt
+18 more
Bertrand Coiffier
Bruce D. Cheson
Herbert Aaron Eradat
Ian Flinn
Jacqueline Claudia Barrientos
Jeff Porter Sharman
John M. Pagel
Michael J. Hallek
Nicole Lamanna
Paolo Ghia
Peter Hillmen
Richard R. Furman
Steven E. Coutre
Susan Mary O'Brien
Thomas J. Ervin
Thomas J. Kipps
Thomas Michael Jahn
Yeonhee Kim
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
1
2